News

| Filed under Company News

Company News: Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

— Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology

— Enabling short-term commercialization of NGS-based molecular microbiology

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing. To this end, Curetis has signed a Supply and Authorization Agreement as well as a further R&D Collaboration and Service Agreement with MGI, a fully-owned subsidiary of BGI Group, one of the world’s leading genome sequencing centers headquartered in Shenzhen, Guangdong, P. R. China.

Read more…

| Filed under Company News

Company News: Curetis Expects Near-Term FDA Decision on De Novo Request

– Review of the Unyvero System and Lower Respiratory Tract (LRT) Cartridge is nearing completion

– U.S. commercial team and operational infrastructure in place

Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today provided a status update on the FDA De Novo filing for the Company’s Unyvero System and LRT Cartridge for the diagnosis of lower respiratory tract infections.

Read more…

| Filed under Company News

Company News: BioNTech Secures USD 270 Million in Series A Financing

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding.

Read more…